A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients
NCT ID: NCT00005764
Last Updated: 2005-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
100 participants
INTERVENTIONAL
2000-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lamivudine/Zidovudine
Abacavir sulfate
Lamivudine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Are HIV-positive.
* Are at least 18 years old.
* Agree not to have intercourse 2 weeks before, during, and 2 weeks after study or agree to use effective methods of birth control.
* Have had HIV-1 RNA levels less than 400 copies/ml on the 2 most recent measurements.
* Have at least 1 of the following situations:
* (a) at least 1 of the following: (1) decrease in facial fat, (2) decrease in fat in lower limbs, or (3) decrease in fat in buttocks area; or
* (b) an increase in lactate level greater than 2.2 mmol/L at the screening visit plus at least 1 of the following: (1) decrease in facial fat, (2) decrease in fat in lower limbs, or (3) decrease in fat in the buttocks area; or
* (c) an increase in lactate level greater than 2.2 mmol/L at screening visit plus at least 2 of the following: (1) shortness of breath, (2) weakness, (3) fast heartbeat, (4) recent weight loss (10 lbs. within the past 2 months), (5) pain and/or bloating in the abdomen, (6) nausea and/or vomiting and/or lack of appetite; or
* (d) lactate level greater than 3.2 mmol/L at the screening visit.
* Are able to read at a sixth-grade level.
* Have taken d4T consistently for the 6 months before entering study.
Exclusion Criteria
* Have diabetes or kidney failure.
* Have any condition that makes them unable to participate in this study.
* Are unable to take medications by mouth.
* Have serious medical conditions, such as congestive heart failure or other heart disease, which would affect the safety of the patient.
* Are taking or have taken abacavir plus Retrovir or Combivir.
* Are pregnant or breast-feeding.
* Are enrolled in other clinical studies.
* Have had a reaction to or are unable to take abacavir and have taken Retrovir in the past.
* Have taken hydroxyurea within the past 3 days or plan to take this drug during the study.
* Have had chemotherapy or radiation therapy within 4 weeks prior to screening visit (except for local treatment for Kaposi's sarcoma) or plan to have such treatment during the study.
* Have taken drugs that affect the immune system, such as systemic corticosteroids, interleukins, vaccines, or interferons, within 4 weeks prior to the screening visit.
* Have had an HIV vaccine within 3 months of the screening visit.
* Have taken recombinant Human Growth Hormone (r-hGH), megestrol acetate, medicines containing oxandrolone, oxymetholone, nandrolone, DHEA, or other testosterone derivatives, or glucocorticoids or other systemic steroids (except inhaled and topical steroids) in the last 4 months or plan to take these drugs during the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Glaxo Wellcome
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
THE Clinic
Los Angeles, California, United States
Tower Infectious Disease Med Ctr
Los Angeles, California, United States
St Lukes Medical Group
San Diego, California, United States
UCSD Treatment Ctr
San Diego, California, United States
Dupont Circle Physicians Group
Washington D.C., District of Columbia, United States
North Broward Hosp District / HIV Clinical Research
Fort Lauderdale, Florida, United States
Duval County Health Department
Jacksonville, Florida, United States
Infectious Disease Research Institute Inc
Tampa, Florida, United States
Northstar Med Clinic
Chicago, Illinois, United States
Jersey Shore Med Ctr
Neptune City, New Jersey, United States
South Jersey Infectious Diseases Inc
Somers Point, New Jersey, United States
Infectious Disease Specialists of NJ
Union, New Jersey, United States
Infectious Diseases Assoc of Brooklyn
Brooklyn, New York, United States
Long Island College Hospital
Brooklyn, New York, United States
Mt Vernon Hospital
Mount Vernon, New York, United States
Dr Lawrence Fontana
New York, New York, United States
Liberty Medical / Cabrini Hospital / Dept of Infec Diseases
New York, New York, United States
Howard Grossman
New York, New York, United States
Boriken Neighborhood Health Center
New York, New York, United States
Bronx Veterans Affairs Med Ctr
The Bronx, New York, United States
Univ of North Carolina / SOCA
Chapel Hill, North Carolina, United States
Summa Health System
Akron, Ohio, United States
Case Western Reserve Univ
Cleveland, Ohio, United States
Philadelphia Veterans Administration Med Ctr
Philadelphia, Pennsylvania, United States
Anderson Clinical Research
Pittsburgh, Pennsylvania, United States
Central Texas Clinical Research
Austin, Texas, United States
Gathe, Joseph, M.D.
Houston, Texas, United States
Diversified Med Practices, PA
Houston, Texas, United States
Univ of Texas / Med School at Houston
Houston, Texas, United States
Hampton Roads Med Specialists
Hampton, Virginia, United States
Swedish Med Ctr
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ESS40010
Identifier Type: -
Identifier Source: secondary_id
238T
Identifier Type: -
Identifier Source: org_study_id